|Bid||248.00 x 100|
|Ask||250.80 x 100|
|Day's Range||250.51 - 253.61|
|52 Week Range||223.02 - 333.65|
|PE Ratio (TTM)||15.71|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
BIIB reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen, the state’s largest local drug company by market cap and headcount, is about to lose yet another top executive. Kenneth DiPietro plans to step down as executive vice president of human resources ...